On June 3, 2025, Kiniksa Pharmaceuticals held its Annual Meeting of Shareholders, where proposals for director re-elections and auditing firm appointments were overwhelmingly approved by shareholders, alongside plans to enhance capital structure with shares worth approximately $6,976.33.